BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8509824)

  • 1. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.
    Kruse CA; Mitchell DH; Kleinschmidt-DeMasters BK; Bellgrau D; Eule JM; Parra JR; Kong Q; Lillehei KO
    J Neurooncol; 1993 Feb; 15(2):97-112. PubMed ID: 8509824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats.
    Fleshner M; Watkins LR; Redd JM; Kruse CA; Bellgrau D
    Cell Transplant; 1992; 1(4):307-12. PubMed ID: 1344303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
    Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
    Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K
    Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
    Carson WE; Jakowatz JG; Yamamoto R; Fitzgerald T; Gupta S; Vayuvegula B; Lucci JA; Beckman MT; Dulkanchainun S; Granger GA
    J Immunother (1991); 1991 Apr; 10(2):131-40. PubMed ID: 2043593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
    Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
    Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.
    Matsuura H; Imaya H
    Cancer Immunol Immunother; 1991; 33(1):50-3. PubMed ID: 2021958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
    Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
    J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.